Korro to participate in upcoming investor conferences

Cambridge, mass., nov. 21, 2024 (globe newswire) -- korro bio, inc. (korro) (nasdaq: krro) a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing rna for both rare and highly prevalent diseases, today announced that members of management will participate in the following investor conferences:
KRRO Ratings Summary
KRRO Quant Ranking